MTOR E2014K

CI-VAR-00000696Explore in graph →NP_004949.1:p.Glu2014LysNM_004958.4:c.6040G>AClinVar 376131 CIViC 572

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Transitional Cell Carcinoma1
MTOR E2014K AND MTOR E2419K	Everolimus + PazopanibCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID1438 A phase 1 clinical trial identified a patient with chemotherapy-refractory urothelial carcinoma who had complete radiographic response lasting 14 months after combined everolimus and pazopanib treatme… (full text at CIViC) PMID 24625776 · Wagle et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.